Abstract
Chronic pain is a complex, debilitating, and escalating health problem worldwide, impacting 1 in 5 adults. Current treatment is compromised by dose-limiting side effects, including high abuse liability, loss of ability to function socially and professionally, fatigue, drowsiness, and apathy. PICK1 has emerged as a promising target for the treatment of chronic pain conditions. Here, we developed and characterized a cell-permeable fatty acid–conjugated bivalent peptide inhibitor of PICK1 and assessed its effects on acute and chronic pain. The myristoylated PICK1 inhibitor, myr-NPEG4-(HWLKV)2 (mPD5), self-assembled into core-shell micelles that provided favorable pharmacodynamic properties and relieved evoked mechanical and thermal hypersensitivity as well as ongoing hypersensitivity and anxiodepressive symptoms in mouse models of neuropathic and inflammatory pain following subcutaneous administration. No overt side effects were associated with mPD5 administration, and it had no effect on acute nociception. Finally, neuropathic pain was relieved far into the chronic phase (18 weeks after spared nerve injury surgery) and while the effect of a single injection ceased after a few hours, repeated administration provided pain relief lasting up to 20 hours after the last injection.
Authors
Kathrine Louise Jensen, Nikolaj Riis Christensen, Carolyn Marie Goddard, Sara Elgaard Jager, Gith Noes-Holt, Ida Buur Kanneworff, Alexander Jakobsen, Lucía Jiménez-Fernández, Emily G. Peck, Line Sivertsen, Raquel Comaposada Baro, Grace Anne Houser, Felix Paul Mayer, Marta Diaz-delCastillo, Marie Løth Topp, Chelsea Hopkins, Cecilie Dubgaard Thomsen, Ahmed Barakat Ibrahim Soltan, Frederik Grønbæk Tidemand, Lise Arleth, Anne-Marie Heegaard, Andreas Toft Sørensen, Kenneth Lindegaard Madsen
Figure 4
Efficacy of mPD5 in neuropathic pain, diabetic neuropathy, bone cancer–induced pain, and acute nociception.
